ArticleCancers2022
The Prognostic Reliability of Lymphovascular Invasion for Patients with T3N0 Colorectal Cancer in Adjuvant Chemotherapy Decision Making.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Prognostic significance of lymphovascular invasion in colorectal mucinous adenocarcinoma after curative resection: a nationwide multi-center retrospective cohort study.Journal of gastrointestinal oncology · 2026Article
- An interpretable machine learning model combining MRI-DKI habitat radiomic features and clinical biomarkers for noninvasive prediction of lymphatic metastasis in rectal cancer: a prospective study.Insights into imaging · 2026Article
- A CT-based radiomics model for preoperative prediction of lymphovascular invasion in colorectal cancer.Frontiers in oncology · 2026Article
- Integrating lymphovascular and perineural invasion into TNM staging: a novel ITNM system for enhanced prognostic stratification in colorectal cancer.Frontiers in oncology · 2026Article
- The role of the lymphatic network in colorectal cancer: anatomy, molecular drivers and management.Annals of gastroenterology · 2026Review
- Noninvasive prediction of lymphovascular invasion in rectal cancer without lymph node metastasis using a SHAP-interpretable combined model integrating MRI radiomics features and clinical immune-inflammatory biomarkers: a bicenter study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Deep Learning Predicts Lymphovascular Invasion Status in Muscle Invasive Bladder Cancer Histopathology.Annals of surgical oncology · 2025Article
- Clinical Association of Negative Lymph Nodes With Adjuvant Chemotherapy in Patients With T3N0 Rectal Cancer.Gastroenterology research and practice · 2025Article
- Lymphovascular invasion in colorectal cancers: can we predict it preoperatively?Annals of coloproctology · 2024Article
- Article
- Prognostic Factors Influencing Survival in Stage II and Stage III Colorectal Cancer Patients.Cureus · 2023Article
- Prognostic Significance of Lymphatic Vessel Invasion and Density in Colorectal Carcinoma: A Systematic Review and Meta-analysis.Cancer diagnosis & prognosisReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Lymphovascular invasion (LVI) is a high-risk feature guiding decision making for adjuvant chemotherapy. We evaluated the prognostic importance and reliability of LVI as an adjuvant chemotherapy indicator in 1634 patients with pT3N0 colorectal cancer treated with curative radical resection between 2012 and 2016. LVI and perineural invasion (PNI) were identified in 382 (23.5%) and 269 (16.5%) patients, respectively. In total, 772 patients received adjuvant chemotherapy. The five-year recurrence-free survival (RFS) and OS rates were 92% and 94.8%, respectively. Preoperative obstruction, PNI, and positive margins were significantly associated with RFS and OS; however, adjuvant chemotherapy and LVI were not. Pathologic slide central reviews of 242 patients using dual D2-40 and CD31 immunohistochemical staining was performed. In the review cohort, the diagnosis of LVI and PNI was changed in 82 (33.9%) and 61 (25.2%) patients, respectively. Reviewed LVI, encompassing small vessel invasion, lymphatic invasion, and large vessel invasion, was not an independent risk factor associated with OS but was related to RFS. The prognostic importance of LVI and adjuvant chemotherapy was not defined because LVI may be underrecognized in pathologic diagnoses using hematoxylin and eosin staining slides only, leading to low recurrence rate predictions. Using LVI as a guiding factor for adjuvant chemotherapy requires further consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.